FOLFOX-HAIC is effective in early-, intermediate-, and advanced-stage hepatocellular carcinoma [2∗, 3∗, 4∗, 5∗, 6, 7, 8, 9, 10, 11, 12∗, 13∗]. The prospective study of FOLFOX-HAIC is shown in Table 1, and all studies met the primary endpoint. For the resectable hepatocellular carcinoma with microvascular invasion, postoperative adjuvant FOLFOX-HAIC can improve the disease-free survival (20.3 [95% CI, 10.4 to 30.3] vs 10.0 months [95% CI, 6.8 to 13.2], HR, 0.59 [95% CI, 0.43 to 0.81], p = 0.001)